Paul F. Engstrom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paul F. Engstrom has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- Leonard B. Saltz
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
1 shared publication
Latest Publications
- 1 November 2008
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 28 (11P2) , 18S-20S
Systemic Therapy for Advanced or Metastatic Colorectal Cancer: National Comprehensive Cancer Network Guidelines for Combining Anti‐Vascular Endothelial Growth Factor and Anti‐Epidermal Growth Factor Receptor Monoclonal Antibodies with Chemotherapy
During the past decade, new therapies for colorectal cancer have emerged that significantly prolong survival times. The introduction of these new agents has resulted in changes in colorectal cancer treatment patterns; clinicians are now able to optimize therapy and minimize toxicity by developing individualized patient treatment plans using a variety of agents. Biologic agents, including bevacizumab, an anti‐vascular endothelial growth factor (VEGF) monoclonal antibody, and cetuximab and panitumumab, anti‐epidermal growth factor receptor (EGFR) monoclonal antibodies, are among the new therapies now recommended by the National Comprehensive Cancer Network (NCCN) colon and rectal cancer treatment guidelines for use in first‐, second‐, and/or third‐line colorectal cancer therapy. According to the NCCN guidelines, patients with advanced or metastatic colorectal cancer who are without contraindications are candidates to receive the anti‐VEGF and anti‐EGFR monoclonal antibodies at some point during the treatment course.
- 1 November 2008
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 28 (11P2) , 18S-20S
Systemic Therapy for Advanced or Metastatic Colorectal Cancer: National Comprehensive Cancer Network Guidelines for Combining Anti‐Vascular Endothelial Growth Factor and Anti‐Epidermal Growth Factor Receptor Monoclonal Antibodies with Chemotherapy
During the past decade, new therapies for colorectal cancer have emerged that significantly prolong survival times. The introduction of these new agents has resulted in changes in colorectal cancer treatment patterns; clinicians are now able to optimize therapy and minimize toxicity by developing individualized patient treatment plans using a variety of agents. Biologic agents, including bevacizumab, an anti‐vascular endothelial growth factor (VEGF) monoclonal antibody, and cetuximab and panitumumab, anti‐epidermal growth factor receptor (EGFR) monoclonal antibodies, are among the new therapies now recommended by the National Comprehensive Cancer Network (NCCN) colon and rectal cancer treatment guidelines for use in first‐, second‐, and/or third‐line colorectal cancer therapy. According to the NCCN guidelines, patients with advanced or metastatic colorectal cancer who are without contraindications are candidates to receive the anti‐VEGF and anti‐EGFR monoclonal antibodies at some point during the treatment course.
- 1 October 2003
Update: colorectal cancer guidelines.